Join Growin Stock Community!

Equillium, inc.EQ.US Overview

US StockHealthcare
(No presentation for EQ)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EQ AI Insights

EQ Overall Performance

EQ AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EQ Recent Performance

-7.03%

Equillium, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

EQ PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EQ Key Information

EQ Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EQ Profile

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Price of EQ

EQ FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EQ Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
25.23
PB Ratio
3.41
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-555.94%
Revenue Growth (YoY)
-90.43%
Profit Growth (YoY)
-90.43%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
25.23
PB Ratio
3.41
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-555.94%
Revenue Growth (YoY)
-90.43%
Profit Growth (YoY)
-90.43%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is EQ's latest earnings report released?

    The most recent financial report for Equillium, inc. (EQ) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EQ's short-term business performance and financial health. For the latest updates on EQ's earnings releases, visit this page regularly.

  • How is EQ's revenue growth?

    In the latest financial report, Equillium, inc. (EQ) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does EQ have?

    As of the end of the reporting period, Equillium, inc. (EQ) had total debt of 745K, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EQ have?

    At the end of the period, Equillium, inc. (EQ) held Total Cash and Cash Equivalents of 33.12M, accounting for 0.96 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of EQ?

    Equillium, inc. (EQ)'s Free Cash Flow (FCF) for the period is -8.43M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 10.11% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EQ?

    The latest valuation data shows Equillium, inc. (EQ) has a Price-To-Earnings (PE) ratio of -2.1 and a Price/Earnings-To-Growth (PEG) ratio of 0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.